Do you consider using 160 mg osimertinib in patients with EGFR-positive metastatic NSCLC to the brain?  

The BLOOM study [Yang et al., PMID 31809241] was the first to address the question of CNS dosage for patients with EGFR mutant NSCLC with brain metastases. In this, patients with cytologically confirmed leptomeningeal (LM) disease received osimertinib 160 mg once daily. LM disease was assessed by bl...